These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978 [TBL] [Abstract][Full Text] [Related]
3. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330 [TBL] [Abstract][Full Text] [Related]
5. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463 [TBL] [Abstract][Full Text] [Related]
7. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899 [TBL] [Abstract][Full Text] [Related]
8. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952 [TBL] [Abstract][Full Text] [Related]
9. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction. Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390 [TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
11. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F Oncology; 2013; 84(4):191-9. PubMed ID: 23328390 [TBL] [Abstract][Full Text] [Related]
12. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797 [TBL] [Abstract][Full Text] [Related]
13. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142 [TBL] [Abstract][Full Text] [Related]
14. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861 [TBL] [Abstract][Full Text] [Related]
15. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576 [TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790 [TBL] [Abstract][Full Text] [Related]
17. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134 [TBL] [Abstract][Full Text] [Related]
18. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083 [TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients. Messager M; Neofytou K; Chaudry MA; Allum WH Eur J Surg Oncol; 2015 Oct; 41(10):1316-23. PubMed ID: 26166786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]